Objective measures of smoking and caffeine intake and the risk of adverse pregnancy outcomes
International Journal of Epidemiology · 2023
DOI: 10.1093/ije/dyad123 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Epidemiology, 2023. Verfasst von Roshan J Selvaratnam und 5 weiteren Autor:innen. Beteiligte Einrichtung: The Ritchie Centre, Department of Obstetrics and Gynaecology, Monash University, VIC, Melbourne, Australia. Hauptthemen laut MEDLINE: Pregnancy Outcome, Caffeine. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, Medical Research Council, National Institute for Health Research.
Abstract (Originalsprache)
Background
In pregnancy, women are encouraged to cease smoking and limit caffeine intake. We employed objective definitions of smoking and caffeine exposure to assess their association with adverse outcomes.
Methods
We conducted a case cohort study within the Pregnancy Outcome Prediction study to analyse maternal serum metabolomics in samples from 12, 20, 28 and 36 weeks of gestational age. Objective smoking status was defined based on detectable cotinine levels at each time point and objective caffeine exposure was based on tertiles of paraxanthine levels at each time point. We used logistic and linear regression to examine the association between cotinine, paraxanthine and the risk of pre-eclampsia, spontaneous pre-term birth (sPTB), fetal growth restriction (FGR), gestational diabetes mellitus and birthweight.
Results
There were 914 and 915 women in the smoking and caffeine analyses, respectively. Compared with no exposure to smoking, consistent exposure to smoking was associated with an increased risk of sPTB [adjusted odds ratio (aOR) = 2.58, 95% CI: 1.14 to 5.85)] and FGR (aOR = 4.07, 95% CI: 2.14 to 7.74) and lower birthweight (β = –387 g, 95% CI: –622 g to –153 g). On univariate analysis, consistently high levels of paraxanthine were associated with an increased risk of FGR but that association attenuated when adjusting for maternal characteristics and objective—but not self-reported—smoking status.
Conclusions
Based on objective data, consistent exposure to smoking throughout pregnancy was strongly associated with sPTB and FGR. High levels of paraxanthine were not independently associated with any of the studied outcomes and were confounded by smoking.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Ritchie Centre, Department of Obstetrics and Gynaecology, Monash University, VIC, Melbourne, Australia.
- Department of Obstetrics and Gynaecology, University of Cambridge, Cambridge, UK.
- Centre for Trophoblast Research, Department of Physiology, Development and Neuroscience, University of Cambridge, Cambridge, UK.
ORCID-Profile: Roshan J Selvaratnam, Ulla Sovio, Emma Cook, Francesca Gaccioli, D Stephen Charnock-Jones
Förderung
- Wellcome Trust
- Medical Research Council
- National Institute for Health Research
- Cambridge Biomedical Research Centre
- Women’s Health theme
- National Health Service
- Department of Health and Social Care
Zitieren
APA
Selvaratnam, R. J., Sovio, U., Cook, E., Gaccioli, F., Charnock-Jones, D. S., & Smith, G. C. S. (2023). Objective measures of smoking and caffeine intake and the risk of adverse pregnancy outcomes. International Journal of Epidemiology. https://doi.org/10.1093/ije/dyad123
Vancouver
Selvaratnam RJ, Sovio U, Cook E, Gaccioli F, Charnock-Jones DS, Smith GCS. Objective measures of smoking and caffeine intake and the risk of adverse pregnancy outcomes. International Journal of Epidemiology. 2023. doi:10.1093/ije/dyad123
BibTeX
@article{Selvaratnam2023,
author = {Selvaratnam, Roshan J and Sovio, Ulla and Cook, Emma and Gaccioli, Francesca and Charnock-Jones, D Stephen and Smith, Gordon C S},
title = {Objective measures of smoking and caffeine intake and the risk of adverse pregnancy outcomes},
journal = {International Journal of Epidemiology},
year = {2023},
doi = {10.1093/ije/dyad123}
}
EUVIMED